Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05938270 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

A Phase 1 study of Prostate Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
120
Enrollment target
19
Study locations

NCT05938270 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 120 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 19 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05938270, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
19
Study locations

Study Summary

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Saruparib (AZD5305)
  • DRUG Darolutamide
  • OTHER No Treatment

Study Locations (19)

Other

  • Research Site - Melbourne
  • Research Site - South Brisbane
  • Research Site - Amsterdam
  • Research Site - Nijmegen
  • Research Site - Barcelona
  • Research Site - Barcelona
  • Research Site - Madrid
  • Research Site - Valencia
  • Research Site - Ankara
  • Research Site - Ankara
  • Research Site - Istanbul
  • Research Site - Cambridge
  • Research Site - Manchester
  • Research Site - Newcastle upon Tyne

Michigan

  • Research Site - Detroit

Rhode Island

  • Research Site - Providence

British Columbia

  • Research Site - Vancouver

Ontario

  • Research Site - Toronto

Quebec

  • Research Site - Québec

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-09-21
Est. Completion 2026-08-17
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05938270

The ClinicalTrials.gov registry entry for NCT05938270 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Saruparib (AZD5305) is the first listed.

NCT05938270 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, Michigan, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT05938270 about?

NCT05938270 is a clinical study titled "A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.". A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

What is the current status of trial NCT05938270?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-09-21. Estimated completion is 2026-08-17.

What conditions does trial NCT05938270 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05938270?

The interventions under investigation include: Saruparib (AZD5305) (DRUG), Darolutamide (DRUG), No Treatment (OTHER).

Who is sponsoring clinical trial NCT05938270?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05938270 being conducted?

This trial has 19 study locations across Michigan, Rhode Island, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.